Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Daiichi Sankyo Still Faces Claims Over Injectable Anemia Drug

Jan. 29, 2020, 9:09 PM

Daiichi Sankyo Co. and its unit American Regent Inc. must keep defending a woman’s suit alleging an injectable iron deficiency anemia drug caused a serious blood chemistry imbalance, after the Eastern District of Pennsylvania rejected its preemption arguments.

Katherine Crockett alleges Injectafer caused her severe hypophosphatemia, a low blood phosphate level, which led to pain, weakness, and constant fatigue.

Daiichi and American Regent failed to show that federal drug labeling law preempts Crockett’s state-law claims alleging inadequate warning and design defect, the U.S. District Court for the Eastern District of Pennsylvania said.

The drugmakers argued that Crockett’s claims are barred ...